Teva Pharmaceutical Industries' second quarter revenue beats on 43% innovative brand growth, though EPS misses due to acquisition costs.

Teva reported second quarter 2026 revenues of $4.1 billion, a 1% decrease year-over-year, while non-GAAP EPS was $0.02, down from $0.66 in the prior-year period. The results were driven by strong growth in key innovative brands, which was offset by lower generics revenue and significant expenses related to the acquisition of Emalex Biosciences.

Key Highlights

• Key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively generated over $1 billion in revenue, growing 43% year-over-year in local currency.
• AUSTEDO global revenue grew 40% year-over-year in local currency to $696 million, continuing to drive the company's 'Pivot to Growth' strategy.
• Overall revenue was pressured by a 15% decrease in global generics revenue due to increased competition for lenalidomide (a generic version of Revlimid).
• Non-GAAP EPS of $0.02 was heavily impacted by expenses from the acquisition of Emalex Biosciences, which accounted for a negative $0.61 per share impact.